SRR8518243
— · E
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- E
- subtype
- E
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.540
- MYC_TARGETS_V1+0.490
- E2F_TARGETS+0.450
- G2M_CHECKPOINT+0.400
- DNA_REPAIR+0.230
- SPERMATOGENESIS+0.180
- PANCREAS_BETA_CELLS+0.160
- UNFOLDED_PROTEIN_RESPONSE+0.160
- OXIDATIVE_PHOSPHORYLATION+0.140
- NOTCH_SIGNALING+0.000
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.590
- ANGIOGENESIS-0.570
- INTERFERON_GAMMA_RESPONSE-0.530
- INTERFERON_ALPHA_RESPONSE-0.520
- IL6_JAK_STAT3_SIGNALING-0.510
- TNFA_SIGNALING_VIA_NFKB-0.510
- COAGULATION-0.490
- TGF_BETA_SIGNALING-0.480
- COMPLEMENT-0.470
- APICAL_JUNCTION-0.460
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
2 twins match this tumor's tissue · 8 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_ZXYDSBM9 | medulloblastoma | — | 0.955 |
| 2 | BS_QHS3V0GP | Embryonal tumors | — | 0.954 |
| 3 | BS_K74PZET7 | medulloblastoma | — | 0.944 |
| 4 | SRR5088911 | — | — | 0.944 |
| 5 | BS_TZVFR600 | medulloblastoma | — | 0.934 |
| 6 | SAMN03290891 | — | — | 0.933 |
| 7 | BS_GE2RVZE6 | medulloblastoma | — | 0.932 |
| 8 | BS_JFB984RG | medulloblastoma | — | 0.932 |
| 9 | BS_HZE3KYZ1 | medulloblastoma | — | 0.930 |
| 10 | BS_9NZ2D6AD | medulloblastoma | — | 0.929 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 9 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.540 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.490 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.450 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.400 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.230 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.180 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.160 | Cobimetinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.160 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.140 | Remibrutinib | — uncovered |